Clinical Trials - June 19, 2025
BioArctic to initiate next cohorts in Phase 2a study
The interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated.
Clinical Trials - June 18, 2025
Kancera reports positive top-line results
The company has announced results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer.
Clinical Trials - June 18, 2025
Abera announces new study results
The company has presented results from a recently completed study that further demonstrates the potential of its vaccine platform for pandemic preparedness.
Clinical Trials - June 10, 2025
LEO Pharma initiates Phase 2a trial
The phase 2a proof-of-concept DELTA NEXT trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP).
Clinical Trials - June 4, 2025
OncoZenge appoints LINK Medical to execute Phase 3 feasibility study
LINK Medical has been engaged to conduct a feasibility study in Europe for the company’s planned Phase 3 study for European approval of BupiZenge.
Clinical Trials - May 26, 2025
Active lymphoma eliminated in two out of three patients in the first cohort of Elicera’s CARMA study
Preliminary principal investigator-assessed outcomes from the first patient cohort in the ongoing Phase I/IIa CARMA study with ELC-301 show that two out of three treated patients had no active lymphoma detected on specialized scans, achieving a complete metabolic response.
